McCarron Frances N, Yoshino Osamu, Müller Philip C, Wang Huaping, Wang Yifan, Ricker Ansley, Mantha Rohit, Driedger Michael, Beckman Michael, Clavien Pierre-Alain, Vrochides Dionisios, Martinie John B
Division of HPB Surgery, Department of Surgery, Carolinas Medical Center, Atrium Health, Charlotte, NC, USA.
Division of Hepatobiliary & Pancreas Surgery, Department of Surgery, Carolinas Medical Center, 1025 Morehead Medical Dr., Suite 600, Charlotte, NC, 2820, USA.
Surg Endosc. 2023 Dec;37(12):9591-9600. doi: 10.1007/s00464-023-10426-x. Epub 2023 Sep 25.
Robotic pancreaticoduodenectomy (RPD) is an emerging alternative to open pancreaticoduodenectomy (OPD). Although RPD offers various theoretical advantages, it is used in less than 10% of all pancreaticoduodenectomies. The aim of this study was to report our 10-year experience and compare RPD outcomes with international benchmarks for OPD.
A retrospective review of a prospectively maintained institutional database was performed of consecutive patients who underwent RPD between January 2011 and December 2021. Patients were categorized into low-risk and high-risk groups according to the selection criteria set by the benchmark study. Their outcomes were compared to the international benchmark cut off values. Outcomes were then evaluated over time to identify improvements in practice and establish a learning curve.
Of 201 RPDs, 36 were low-risk and 165 high-risk patients. Compared to the OPD benchmarks, outcomes of low-risk patients were within the cutoff values. High-risk patients were outside the cutoff for blood transfusions (26% vs. ≤ 23%), overall complications (78% vs. ≤ 73%), grade I-II complications (68% vs. ≤ 62%), and readmissions (22% vs ≤ 21%). Oncologic outcomes for high-risk patients were within benchmark cutoffs. Cases at the end of the learning curve included more pancreatic cancer (42% from 17%) and fewer low-risk patients (10% from 24%) than those at the beginning. After 41 RPD there was a decline in conversion rates and operative time. Between 95 and 143 cases operative time, transfusion rates, and LOS declined significantly. Complications did not differ over time.
RPD yields results comparable to the established benchmarks in OPD in both low- and high-risk patients. Along the learning curve, RPD evolved with the inclusion of more high-risk cases while outcomes remained within benchmarks. Addition of a robotic HPB surgery fellowship did not compromise outcomes. These results suggest that RPD may be an option for high-risk patients at specialized centers.
机器人胰十二指肠切除术(RPD)是开放性胰十二指肠切除术(OPD)的一种新兴替代方案。尽管RPD具有多种理论优势,但在所有胰十二指肠切除术中的应用比例不到10%。本研究的目的是报告我们10年的经验,并将RPD的结果与OPD的国际基准进行比较。
对2011年1月至2021年12月期间连续接受RPD的患者进行回顾性研究,这些患者的数据前瞻性地保存在机构数据库中。根据基准研究设定的选择标准,将患者分为低风险组和高风险组。将他们的结果与国际基准临界值进行比较。然后随时间评估结果,以确定实践中的改进并建立学习曲线。
在201例RPD患者中,36例为低风险患者,165例为高风险患者。与OPD基准相比,低风险患者的结果在临界值范围内。高风险患者在输血(26%对≤23%)、总体并发症(78%对≤73%)、I-II级并发症(68%对≤62%)和再入院率(22%对≤21%)方面超出临界值。高风险患者的肿瘤学结果在基准临界值范围内。与学习曲线开始时相比,学习曲线末期的病例中胰腺癌更多(从17%增至42%),低风险患者更少(从24%降至10%)。在进行41例RPD后,转化率和手术时间有所下降。在95至143例手术之间,手术时间、输血率和住院时间显著下降。并发症随时间无差异。
RPD在低风险和高风险患者中产生的结果与OPD既定基准相当。沿着学习曲线,RPD随着纳入更多高风险病例而发展,同时结果仍在基准范围内。增加机器人肝脏胰腺胆道手术进修项目并未影响结果。这些结果表明,RPD可能是专科中心高风险患者的一种选择。